- Home
- AYTU vs EDSA Comparison
AYTU vs EDSA Comparison
Compare AYTU & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- EDSA
- Stock Information
- Founded
- AYTU N/A
- EDSA 2015
- Country
- AYTU United States
- EDSA Canada
- Employees
- AYTU N/A
- EDSA N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- EDSA Health Care
- Exchange
- AYTU Nasdaq
- EDSA Nasdaq
- Market Cap
- AYTU 15.0M
- EDSA 13.8M
- IPO Year
- AYTU N/A
- EDSA N/A
- Fundamental
- Price
- AYTU $2.24
- EDSA $4.05
- Analyst Decision
- AYTU
- EDSA Strong Buy
- Analyst Count
- AYTU 0
- EDSA 2
- Target Price
- AYTU N/A
- EDSA $39.00
- AVG Volume (30 Days)
- AYTU 32.2K
- EDSA 13.5K
- Earning Date
- AYTU 11-12-2024
- EDSA 08-09-2024
- Dividend Yield
- AYTU N/A
- EDSA N/A
- EPS Growth
- AYTU N/A
- EDSA N/A
- EPS
- AYTU N/A
- EDSA N/A
- Revenue
- AYTU $81,002,000.00
- EDSA N/A
- Revenue This Year
- AYTU N/A
- EDSA N/A
- Revenue Next Year
- AYTU N/A
- EDSA N/A
- P/E Ratio
- AYTU N/A
- EDSA N/A
- Revenue Growth
- AYTU N/A
- EDSA N/A
- 52 Week Low
- AYTU $2.11
- EDSA $2.50
- 52 Week High
- AYTU $3.50
- EDSA $6.46
- Technical
- Relative Strength Index (RSI)
- AYTU 40.89
- EDSA 38.30
- Support Level
- AYTU $2.11
- EDSA $4.00
- Resistance Level
- AYTU $2.44
- EDSA $4.44
- Average True Range (ATR)
- AYTU 0.14
- EDSA 0.25
- MACD
- AYTU -0.02
- EDSA -0.03
- Stochastic Oscillator
- AYTU 17.57
- EDSA 4.77
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.